Cargando…

Comparative study in estrogen-depleted mice identifies skeletal and osteocyte transcriptomic responses to abaloparatide and teriparatide

Osteocytes express parathyroid hormone (PTH)/PTH-related protein (PTHrP) receptors and respond to the PTHrP analog abaloparatide (ABL) and to the PTH 1-34 fragment teriparatide (TPTD), which are used to treat osteoporosis. Several studies indicate overlapping but distinct skeletal responses to ABL o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lv, Zhengtao, Zhang, Jiaming, Liang, Shuang, Zhou, Chenhe, Hu, Dorothy, Brooks, Daniel J., Bouxsein, Mary L., Lanske, Beate, Kostenuik, Paul, Gori, Francesca, Baron, Roland
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619488/ https://www.ncbi.nlm.nih.gov/pubmed/37870958 http://dx.doi.org/10.1172/jci.insight.161932

Ejemplares similares

Effects of abaloparatide and teriparatide on bone resorption and bone formation in female mice()
por: Arlt, Heike, et al.
Publicado: (2020)

SUN-335 Abaloparatide Prevents Unloading-Induced Bone Loss in Adult Rats
por: Teguh, Dian A, et al.
Publicado: (2020)

Teriparatide and Abaloparatide Have a Similar Effect on Bone in Mice
por: Brent, Mikkel Bo, et al.
Publicado: (2021)

Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia
por: Chandler, H., et al.
Publicado: (2019)

Abaloparatide versus teriparatide: a head to head comparison of effects on fracture healing in mouse models
por: Bernhardsson, Magnus, et al.
Publicado: (2018)

Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide
por: Reginster, Jean-Yves, et al.
Publicado: (2018)

Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE
por: Eastell, R., et al.
Publicado: (2019)

Differential effects of abaloparatide and teriparatide on hip cortical volumetric BMD by DXA-based 3D modeling
por: Winzenrieth, R., et al.
Publicado: (2021)

Abaloparatide Exerts Bone Anabolic Effects with Less Stimulation of Bone Resorption-Related Factors: A Comparison with Teriparatide
por: Makino, Akito, et al.
Publicado: (2018)

Abaloparatide exhibits greater osteoanabolic response and higher cAMP stimulation and β‐arrestin recruitment than teriparatide
por: Sahbani, Karim, et al.
Publicado: (2019)

SUN-385 Differential Effects of Abaloparatide and Teriparatide on Hip Cortical Volumetric BMD by DXA-Based 3d Modeling
por: Winzenrieth, Renaud, et al.
Publicado: (2020)

Comparable Initial Engagement of Intracellular Signaling Pathways by Parathyroid Hormone Receptor Ligands Teriparatide, Abaloparatide, and Long‐Acting PTH
por: Sato, Tadatoshi, et al.
Publicado: (2021)

Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis
por: Hong, Pan, et al.
Publicado: (2023)

OR03-2 Different Effects of Abaloparatide and h-PTH(1-34) on Osteoclastogenesis and Bone Resorption
por: Arlt, Heike, et al.
Publicado: (2019)

302 Abaloparatide as a novel therapy for posttraumatic osteoarthritis
por: Landgrave, Samantha H., et al.
Publicado: (2022)

Effects of systemically administered abaloparatide, an osteoanabolic PTHrP analog, as an adjuvant therapy for spinal fusion in rats
por: Arlt, Heike, et al.
Publicado: (2020)

Parathyroid Hormone-Related Peptide and Its Analog, Abaloparatide, Attenuate Lethal Myocardial Ischemia-Reperfusion Injury
por: Wider, Joseph, et al.
Publicado: (2022)

Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States
por: Le, Quang A., et al.
Publicado: (2018)

Characterizing patients initiating abaloparatide, teriparatide, or denosumab in a real-world setting: a US linked claims and EMR database analysis
por: Imel, E.A., et al.
Publicado: (2020)

Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study
por: Cosman, F., et al.
Publicado: (2022)

Proximal Femur Responses to Sequential Therapy With Abaloparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis by 3D Modeling of Hip Dual‐Energy X‐Ray Absorptiometry (DXA)
por: Winzenrieth, Renaud, et al.
Publicado: (2022)

Sex‐Specific Differences in G(s)α‐Mediated Signaling Downstream of PTH1R Activation by Abaloparatide in Bone
por: Swami, Srilatha, et al.
Publicado: (2022)

Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption
por: Doyle, N., et al.
Publicado: (2017)

Abaloparatide and the Spine: A Narrative Review
por: Thompson, Jeremy C, et al.
Publicado: (2020)

SIKs control osteocyte responses to parathyroid hormone
por: Wein, Marc N., et al.
Publicado: (2016)

Corrigendum: SIKs control osteocyte responses to parathyroid hormone
por: Wein, Marc N., et al.
Publicado: (2017)

Abaloparatide Real‐World Patient Experience Study
por: Gold, Deborah T, et al.
Publicado: (2021)

Osteocyte secreted factors inhibit skeletal muscle differentiation
por: Wood, Charles L., et al.
Publicado: (2017)

Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis
por: Tella, Sri Harsha, et al.
Publicado: (2017)

Partial prevention of glucocorticoid-induced osteocyte deterioration in young male mice with osteocrin gene therapy
por: Mazur, Courtney M., et al.
Publicado: (2022)

Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density
por: Miller, Paul D., et al.
Publicado: (2021)

Scl-Ab reverts pro-osteoclastogenic signalling and resorption in estrogen deficient osteocytes
por: Allison, H., et al.
Publicado: (2020)

Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide
por: McClung, Michael R., et al.
Publicado: (2017)

A FAK/HDAC5 signaling axis controls osteocyte mechanotransduction
por: Sato, Tadatoshi, et al.
Publicado: (2020)

The Efficacy of PTH and Abaloparatide to Counteract Immobilization-Induced Osteopenia Is in General Similar
por: Brent, Mikkel Bo, et al.
Publicado: (2020)

Correction to: Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide
por: McClung, Michael R., et al.
Publicado: (2018)

Osteocyte transcriptome mapping identifies a molecular landscape controlling skeletal homeostasis and susceptibility to skeletal disease
por: Youlten, Scott E., et al.
Publicado: (2021)

Control of Bone Mass and Remodeling by PTH Receptor Signaling in Osteocytes
por: O'Brien, Charles A., et al.
Publicado: (2008)

The Effect of Zoledronic Acid on Bone Microarchitecture and Strength after Denosumab and Teriparatide Administration: DATA‐HD Study Extension
por: Ramchand, Sabashini K., et al.
Publicado: (2022)

Pyrroloquinoline Quinone Prevents Estrogen Deficiency-Induced Osteoporosis by Inhibiting Oxidative Stress and Osteocyte Senescence
por: Geng, Qinghe, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2mmd0fspbgetkqlgc381vio4ki